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We describe a multi-omic approach to understanding the effects that the anti-malarial drug
pyrimethamine has on immune physiology in rhesus macaques (Macaca mulatta). Whole
blood and bone marrow (BM) RNA-Seq and plasma metabolome profiles (each with over
15,000 features) have been generated for five naïve individuals at up to seven timepoints
before, during and after three rounds of drug administration. Linear modeling and Bayesian
network analyses are both considered, alongside investigations of the impact of statistical
modeling strategies on biological inference. Individual macaques were found to be a major
source of variance for both omic data types, and factoring individuals into subsequent
modeling increases power to detect temporal effects. A major component of the whole
blood transcriptome follows the BMwith a time-delay, while other components of variation
are unique to each compartment. We demonstrate that pyrimethamine administration
does impact both compartments throughout the experiment, but very limited perturbation
of transcript or metabolite abundance was observed following each round of drug
exposure. New insights into the mode of action of the drug are presented in the context
of pyrimethamine’s predicted effect on suppression of cell division and metabolism in the
immune system.
Keywords: pyrimethamine, bone marrow, peripheral blood, axes of variation, bayesian network inference, principal
component analysis (PCA)
INTRODUCTION
The Malaria Host-Pathogen Interaction Center (MaHPIC) has
initiated a systems biology program to understand the course
of events and mechanistic processes that occur in the biology
of infected non-human primates (NHPs) and Plasmodium par-
asites over the course of malaria episodes. The long-term goal
is to advance the development of interventions for this major
global parasitic disease (WHO World Malaria Report, 2013).
This research program investigates how NHP-infective species of
Plasmodium that model human malaria caused by P. falciparum
and P. vivax elicit various host responses, develop immunity,
adopt immune-avoidance strategies, and cope with anti-malarial
drugs (Galinski et al., 2013; Wright and Rayner, 2014). We
are integrating diverse data types, including transcriptomics,
metabolomics, lipidomics, proteomics, and innate and adap-
tive immune profiles and performing cross-species comparisons
with multiple different host-parasite infection model combina-
tions. There are many gaps in knowledge relating to Plasmodium
infections including the immune response, the mechanisms of
malaria pathogenesis and multiorgan dysfunction, the adverse
impact on the bone marrow (BM) progenitors and the dynam-
ics of co-infections (Hafalla et al., 2011; Schwenk and Richie,
2011; Frevert and Nacer, 2013; Stanisic et al., 2013). The NHP
models being studied enable more rigorous experimentation
and in-depth analyses than are possible from direct investi-
gations in humans (Deye et al., 2012; Tachibana et al., 2012;
Moreno et al., 2013) and they are well-suited for systems biology
approaches.
In this study, we establish logistics and procedures that lay
the foundation for studies of rhesus macaques (Macaca mulatta)
inoculated with infectious Plasmodium parasites, following which
intermittent antimalarial drug intervention may be required. The
data presented here serve as pilot data, with inoculations consist-
ing of Anopheline mosquito salivary gland preparations lacking
sporozoites, and the analyses begin to show how multiple diverse
datasets can be integrated. We present multi-omic data analy-
ses using top-down approaches to the integration of RNA-Seq
derived transcriptome data from the BM and peripheral blood
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(PB), as well as plasma metabolite data, and complete blood
cell count (CBC) parameters. These data types were obtained
during a 100-day period, at specific timepoints before and after
pyrimethamine administration to five rhesus macaques.
By top-down integration, we mean statistical and machine-
learning strategies that are naïve to the known biochemical anno-
tation of the transcript and metabolite features (Bang et al., 2008;
Giuliani et al., 2014). Our approach is to use principal compo-
nents analysis (PCA) to describe the major sources of variance
(among individual animals or temporal) in each data type, and
then to seek correlations between the major components across
data types (Boedigheimer et al., 2008). We perform standard dif-
ferential gene expression analysis, also asking how the statistical
modeling strategy and data reduction influence identification of
drug-responsive genes, and employ gene set enrichment analysis
to identify pathways of interest. In an attempt to overcome the
limitations of orthogonal PCA, particularly in the context of a
relatively small experiment, we ask whether biologically derived
axes of variation that are known to consistently capture PB vari-
ation in humans, are conserved in macaques and covary with
drug treatment. A bottom-up strategy, starting with known cel-
lular and biochemical pathways from the Kyoto Encyclopedia of
Genes and Genomes (KEGG: Kanehisa and Goto, 2000; Kanehisa
et al., 2014), is contrasted and used to help draw more inferences
about the physiological impact of pyrimethamine particularly
on the BM. Finally, Bayesian network analysis (Bumgarner and
Yeung, 2009; Pei and Shin, 2012) is also applied as an orthogonal
approach with promise for overcoming the conditional depen-
dence of the transcriptome and metabolome in a dataset with
high dimensionality and a small number of samples. The work
flow is shown in Figure 1 including the questions posed by each
mode of analysis and the major conclusions.
The null hypotheses are first that neither host nor drug admin-
istration impact gene expression, and second that the major
variance components of the BM and PB transcriptomes and
plasma metabolome are uncorrelated. Transcriptome data was
collected by RNA-Seq (Wilhelm and Landry, 2009) with a mean
of 40 million paired-end reads for each of 35 BM and 35 PB
samples studied (five macaques each with seven collection time-
points), focusing on transcript abundance for ∼15,000 genes.
Metabolome data was collected by Orbitrap mass spectrome-
try following liquid chromatography (Jones et al., 2012; Soltow
et al., 2013) on two different columns (AE and C18) with ∼6000
and ∼14,500m/z features, respectively. Our expectation was that
drug administration would have global effects on each of the four
omic measures (BM and PB transcriptomes, and AE and C18
generated metabolomes), and that among-individual differences
would be relatively minor. However, we had no pre-conception
of the fraction of genes that would be differentially expressed,
or of the degree of correspondence we would find between the
transcriptomes and metabolome. Since the PB consists of cells
generated in the BM, we expected a temporal delay between these
two compartments with considerable overlap in variance com-
ponents, which would also reflect differences in the counts of
major blood cell types obtained by standard CBC analysis. Herein
we quantify departures from each of these expectations as well
as a general failure to reject the null hypothesis that the blood
transcriptomes and metabolomes are uncorrelated, and discuss
the implications for the mode of action of pyrimethamine.
MATERIALS AND METHODS
EXPERIMENTAL DESIGN
The experimental design of this experiment involving rhe-
sus macaques (Macaca mulatta) was approved by the Emory
University Institutional Animal Care and Use Committee
(IACUC) and is as follows. Five males (RCs13, RWr13, RUn13,
RZe13, and RTi13) approximately 2 years of age were injected
intravenously with a preparation of Anopheles dirus salivary gland
material (prepared similarly to how infectious Plasmodium sporo-
zoites would be purified; Kennedy et al., 2012) and then profiled
for clinical and omic measurements over the course of a 100-
day experiment. The animals were moved into experimental pair
housing (RCs13/RWr13 and RUn13/RZe13) 10 days prior to the
baseline sampling point at Day 0, namely timepoint 1 (TP1). The
fifth macaque (RTi13) was housed alone. Capillary blood sam-
ples collected daily from ear pricks into EDTA-tubes were used to
obtain complete blood cell counts (CBCs), with the exception of
days 51 to 53 when an equipment failure occurred. On days 21,
27, 52, 59, 90, and 98, PB and BM samples were collected com-
prising TPs 2-7. These collections, and that of TP1, were taken
under chemical restraint with ketamine delivered intramuscularly
at 10mg/kg. This dissociative anesthetic has a short elimination
half-life (20–40min) and, to our knowledge, has no known drug
interaction with pyrimethamine. The experimental design does
not, however, allow for distinguishing the effects of the drug or
anesthetic. BM aspirates were obtained from the right or left iliac
crests in an alternating manner for consecutive timepoints and
performed using 18G needles. Immediately after collection BM
samples were transferred into Vacutainer EDTA tubes. PB sam-
ples were collected from the femoral artery into Vacutainer EDTA
tubes. The transcriptomes and metabolomes were interrogated
at seven (TP1-7) and five (TP3-7) timepoints, respectively, as
shown in Figure 1. Pyrimethamine (Sigma-P7771) was delivered
(1mg/kg) intramuscularly once on day 20, and for 3 successive
days starting at days 52 and 90 (TP2, 4, and 6), corresponding
to predicted periods for sub-curative and curative experimental
treatment regimens for malaria infection of macaques.
LIBRARY PREPARATION FOR RNA-SEQ
BM (1ml) was collected into 1.5ml tubes with EDTA, and the
mononuclear cells were purified by density gradient centrifuga-
tion on Lymphoprep (Stem Cell Technologies) solution and pre-
served in RLT buffer (Qiagen) to stabilize mRNA. Whole blood
(3ml) was collected in Tempus tubes (Applied Biosystems) which
preserve mRNA; these samples include erythrocytes, platelets
and granulocytes, and mononuclear lymphocytes. RNA was
extracted from the BM samples using Qiagen RNEasy Mini-
Plus kits following the manufacturer-recommended procedures,
and from PB samples using Tempus-Spin RNA isolation kits
(Life Technologies). The quality of all RNA samples was con-
firmed using a Bioanalyzer, with an RNA Integrity Number (RIN;
Schroeder et al., 2006) greater than 8 recorded for all samples.
Approximately 1µg of total RNA per sample was con-
verted to double-stranded cDNA using poly-A beads to enrich
Frontiers in Cell and Developmental Biology | Systems Biology October 2014 | Volume 2 | Article 54 | 2
Lee et al. Multi-omics of macaque pyrimethamine administration
FIGURE 1 | Experimental Design. (A) Five macaques were each
delivered a sub-curative dose of pyrimethamine at Day 21, and 3-day
curative doses commencing at Days 52 and 90, in each case
immediately following peripheral blood sampling. This results in two
pre-drug, three post-drug, and two inter-drug treatments as indicated.
Metabolome data was not generated for the first two timepoints.
(B) Flow of analytical approaches including major questions asked and
inferences drawn.
for mRNA, and Illumina TruSeq Stranded mRNA Sample
Prep kits to generate strand-specific libraries. As a qual-
ity control, 96 spike-in RNAs of known concentration and
GC proportions (ERCC Spike-In Control, Life Technologies;
Devonshire et al., 2010) were added to constitute approx-
imately 1% of the total RNA for each library. Adapters
were ligated to facilitate 3-plex sequencing on an Illumina
HiSeq2000 at the Yerkes National Primate Center Genomics
Core, aiming for 80 million paired-end 100 base pair (bp)
reads per library. Average insert sizes were in the range of
300–400 bp.
SHORT READ MAPPING AND GENE EXPRESSION QUANTIFICATION
To quantify gene expression, the RNA-Seq reads were mapped to
an early version of a new assembly of the rhesusmacaque (MacaM
assembly, Version 4.0, GenBank accession number PRJNA214746
ID: 214746, created by Aleksey Zimin at the University of
Maryland, Rob Norgren at the University of Nebraska Medical
Center, and their colleagues) using Tophat2 (Trapnell et al.,
2012; Kim et al., 2013). Default options were used with the
exception that the command—library-type fr-secondstrand was
invoked since the reads were generated using a stranded library
preparation method. This allowed us to differentiate between
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sense and antisense transcripts. Rob Norgren and his colleagues
also provided a GTF file (version 4.12) of the annotated MacaM
assembly indicating the exon boundaries of rhesus genes that
was used in our transcriptome analyses to improve the map-
ping accuracy across splice junctions. Only reads that map to
a single location in the genome were included, to ensure high-
confidence mapping. All downstream analyses were performed at
the level of annotated gene: this study does not consider exon-
specific or transcript isoform relative abundance. Transcription
was detected for 15,442 genes. The dataset has been deposited
to the Gene Expression Omnibus archive (GEO) under accession
number GSE58340.
Several quality control steps were used to verify the relia-
bility of the data: linear correlation of estimated abundance of
ERCC spike-in controls with known concentration; confirmation
of 99.9% strand-specificity of the controls; less than 0.1% con-
trol fusion transcripts; and absence of 3′ bias in the controls was
confirmed with RSeqC v2.3.8 software (http://rseqc.sourceforge.
net; Wang et al., 2012). Transcript abundance levels were inferred
using HTSeq v0.5.4p5 (http://www-huber.embl.de/users/anders/
HTSeq/doc; Anders et al., 2014). HTSeq takes the short-read
mapping.bam file from tophat2 and the gene annotation file
which contains the locations of all annotated genes. Since some
libraries were sequenced more deeply than others, the libraries
were normalized before determining differential gene expression
using the gene level expression files with the default parameters of
DESeq version 1.10.1 (http://www.bioconductor.org/packages/
release/bioc/html/DESeq.html; Anders and Huber, 2010).
METABOLOMIC FEATURE QUANTIFICATION
High resolution metabolomics (m/z range 85–2000) was
performed using a liquid chromatography/mass spectrome-
try (LC/MS) approach on a Thermo Orbitrap-Velos Mass
Spectrometer (Thermo Fisher, San Diego, CA) via positive-ion
electrospray ionization (ESI). Two different columns were used
for the LC separation stage: C18 and anion exchange (AE). Each
distinct biological sample was run in triplicate in order to ensure
high reliability of the data, with randomization within batches
(Soltow et al., 2013). MS peaks were called using xMSanalyzer
v1.3.2 (Uppal et al., 2013) with apLCMS v5.9.4 (Yu et al., 2009).
Standard quality control measures were performed, such that fea-
tures with greater than 30% missing values were removed from
the analysis. Since the frequency distributions of all samples were
comparable, no additional normalization was performed, but an
abundance cutoff of 256 peak area units was adopted and all fea-
tures below this were excluded. All downstream analyses utilized
the median values of three technical replicate samples, namely a
single measure per biological sample. The AE and C18 columns
generated 5861 and 14,339m/z and retention time features
respectively, the majority of which are either not yet annotated
or have ambiguous annotation to multiple possible organic com-
pounds. The m/z features are thought to include the majority of
known components of central metabolism, as well as xenobiotics.
STATISTICAL ANALYSIS
After data normalization, the transcriptome andmetabolome lev-
els were log-2-transformed and imported into JMP Genomics
(version 6.0, SAS Institute, Cary, NC). The log-2 transformation
was performed both to ensure that the data is more normally
distributed and to facilitate simple comparison of the magnitude
of differential expression in a symmetrical manner with respect
to up- and down-regulation, as is standard in microarray analy-
sis: plus or minus 1 unit corresponds to a 2-fold change for each
of the datasets. To determine howmuch of the variance in each of
our datasets is explained by our twomeasured factors (animal and
timepoint), we performed a principal components (PC)-variance
component analysis using JMP v6.0 (SAS) for the transcriptomes,
metabolomes, and the CBC data (Boedigheimer et al., 2008).
This consists of generation of all PC explaining up to 90% of
the total variance (12–15 for the transcriptomes and ∼30 for the
metabolomes), regressing each PC on “animal” or “timepoint,”
and generating a weighted average of the squared correlation coef-
ficient (percent variance explained) across all of the PC scores.
Since the low abundance features for metabolomics and tran-
scriptomics both have high coefficients of variation, we set thresh-
olds of 5 log2 units for transcripts and 17 log2 units for metabo-
lites based simply on visual inspection of plots of the coefficient of
variance against average abundance. After estimating the effect of
lower-abundance features on the variance components, they were
removed for all downstream analyses. No attempt was made to
optimize the threshold or systematically evaluate its impact, but
the major conclusions of the study are unlikely to be affected.
To assess whether the major PC capture similar aspects of the
data, the first 10 PC were calculated for the four omics datasets
using JMP. All 780 pairwise correlations of these PC values were
determined, and a Bonferroni multiple comparison adjustment
was used to assess the significance of each pair of PC. Exploratory
partial least square regression analyses were also performed with
MixOmics (González et al., 2012; http://cran.r-project.org/web/
packages/mixOmics/index.html) in an attempt to select variables
that co-vary, but did not reveal significant associations.
BLOOD INFORMATIVE TRANSCRIPT (BIT) AXES
In addition to PCA, we employed a second method, blood infor-
mative transcript (BIT) axes analysis (Preininger et al., 2013).
Briefly, 10 highly co-regulated transcripts in blood (the BIT) cap-
ture each of 9 common axes of variation that are observed in all
human PB gene expression datasets. PC1 for each of these 9 sets
of 10 transcripts provide Axis scores for each individual sample,
and were generated independently for both the PB and BM sam-
ples, using the normalized expression data. We then examined
the dynamics of the axes scores (or their residuals after fitting
“Animal”) over time and used ANOVA to evaluate differences
among the timepoints or animals.
DIFFERENTIAL GENE EXPRESSION
The next step in our analysis was the identification of genes
that are differentially expressed across the experimental condi-
tions (Soneson andDelorenzi, 2013). For between-TP differences,
an ANOVA was performed on each transcript separately using
“animal” as a random effect with five levels and “timepoint”
with seven levels, or “drug” with three levels as the fixed effect.
For the drug exposure factor, we define our three experimental
conditions as before drug exposure (pre-drug; TP1 and TP2), 7
Frontiers in Cell and Developmental Biology | Systems Biology October 2014 | Volume 2 | Article 54 | 4
Lee et al. Multi-omics of macaque pyrimethamine administration
days after the most recent dose (post-drug; TP3, TP5, and TP7),
and 30 days after most recent dose and immediately before the
next dose (inter-drug; TP4 and TP6), as shown in Figure 1. A
Benjamini-Hochberg false discovery rate cutoff of 5% was used to
define differentially expressed genes. These were examined using
hierarchical clustering of the standardized least squares means,
and volcano plots of significance against fold difference between
specific conditions (Wolfinger et al., 2001). The significantly dif-
ferentially expressed genes are reported as a Supplementary flat
file that consists of a list of gene names with their corresponding
F-statistics at http://www.cig.gatech.edu/supplementary-data.
Gene set enrichment analyses were performed using pre-
existing human gene set annotations from the Broad Institute
(Subramanian et al., 2005), considering that the majority of
known genes in the macaque genome have very closely related
syntenic human orthologs (Zhang et al., 2014). We used
the ranked gene list method of GSEA v2.0.14 (http://www.
broadinstitute.org/gsea/index.jsp) to perform the contrast of
interest (pre-vs.-[post plus inter] drug treatment), testing for
enrichment of t-statistics in KEGG pathways and/or GO terms.
Gene sets with a nominal p < 0.001 and an FDR q < 5% were
considered as significant per the recommendations of the GSEA
software manual. Default parameters were used, excluding gene
sets with more than 500 or fewer than 20 genes.
BAYESIAN NETWORK ANALYSIS
For the Bayesian network analyses, only the 1000 most differen-
tially expressed genes (largest F-ratios for the Drug effect) or 500
metabolites were used, so as to ensure computational tractability
of the clustering software while incorporating biologically rele-
vant genes. The transcript abundance measures were the residuals
after fitting “animal” in the ANOVA to remove this large over-
all source of variance, while raw median metabolite abundance
measures were used based on the relatively small contribution of
animal and timepoint to the variance. Custom scripts were writ-
ten in MATLAB and R to perform quality threshold clustering
(Heyer et al., 1999; De Smet et al., 2002) on the mean-centered
expression values, namely the residuals after fitting “animal” to
each gene. A d = 0.3 cluster similarity threshold was employed
as suggested by Heyer et al. (1999). Since the data are normal-
ized and since that similarity threshold is based on a specific type
of correlation metric, it is reasonable to expect that such a value
may be an excellent starting point across transcriptomic studies.
We also performed small perturbations of the cluster similarity
threshold and found that the main differences were in the merg-
ing portions of some smaller clusters into some bigger clusters.
The number and membership of the larger clusters (used for
analysis here) remained similar (data not shown). Only clusters
with at least 10 transcripts (or metabolites) were retained for fur-
ther analysis. Significance and robustness of these clusters were
assessed via permutation tests.
Since robust and accurate Bayesian network inference is typ-
ically very difficult with only 35 observations (five animals and
seven timepoints), we treated genes within clusters as separate
observations of those clusters. We ranked each gene relative to its
correlation with the centroid of the cluster across all 35 samples
(25 for metabolites since TP1 and TP2 were missing) and then
concatenated the top 10 genes into a list of 350 (250) observa-
tions for each of 26 transcript and four metabolite clusters that
satisfied the clustering criteria. We chose to use just the top 10
genes so as to ensure that each node in the network has the same
number of observations (no missing data) and because Bayesian
network inference benchmarking literature has shown that having
a few hundred observations can provide reasonably robust infer-
ence. The selection of 10 genes thus balances robustness with the
number of different clusters that can be analyzed, as increasing
that threshold necessarily eliminates more clusters. Next, the data
was discretized using a mutual information content-preserving
algorithm (Hartemink, 2001), as the Bayesian network analy-
sis is expected to be more robust for discrete data. Briefly, for
each variable, observations are stepwise coalesced into discretized
bins such that the loss in mutual information content between
that variable and all other variables is minimized. The estimated
elbow-point in the remaining mutual information as a function
of the number of discretization levels was then selected as the
desired number of levels (seven for transcriptional and five for
metabolite data). Networks were subsequently generated using
the Sparse Candidate Algorithm (Friedman et al., 1999) of Causal
Explorer in MATLAB (http://www.dsl-lab.org/causal_explorer;
Aliferis et al., 2003). The most robust connections between clus-
ters were identified using subsampling and permutation tests. We
used three shuffled datasets, within which the order of the 10
genes in each cluster was permuted independently, to minimize
the possibility of over-fitting the available data: if the 10 genes
are good representatives of the cluster, then there should not be
much mutual information based solely on a given gene in one
cluster being compared to a specific gene in another cluster, and
so the most robust edges (and least likely to be due to over-fitting)
are the ones that occur in multiple shuffled datasets. For each
of these shuffled datasets we assessed the sensitivity of the infer-
ence method to perturbations in the amount of available data
by performing network inference with 90% subsampling of 1000
replicates of the dataset.
To assess whether the BM clusters are valid in the PB, the PB
data for each of the clusters was used to determine their cen-
troids. The distribution of Pearson correlation coefficients for
each member of the cluster to the centroid was calculated. These
distributions were compared to analogous calculations for ran-
dom samples of the same number of genes for each cluster, using
a one-tailed Kolmogorov–Smirnov test.
To assess whether the BM clusters form a network in the
PB, we used the same 26 clusters from the BM data, identi-
fied the 10 genes closest to the centroid using the PB data for
each cluster, and used concatenated gene data for each cluster to
generate new Bayesian networks. To evaluate whether there are
interactions between transcriptomic and metabolic networks, we
repeated the Bayesian network inference using the 26 BM tran-
script clusters and four plasma metabolite clusters from the C18
column MS data analyzed with essentially the same pipeline. The
same methods as described above were used to form this inte-
grated network, except that for the transcriptional data only the
five timepoints corresponding to the metabolomics timepoints
were kept, the data discretization was performed jointly on the
combined datasets, and metabolomics data was unit normalized.
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RESULTS
VARIANCE COMPONENTS OF OMIC DATA
The experimental design consisted of a 100 day mock-infection
cycle of M. mulatta that follows a similar time course as will
be used for a series of Plasmodium infections in later MaHPIC
studies (Figure 1). Each of five monkeys was transferred, in two
pairs and a single, to indoor cages at the Yerkes National Primate
Research Center in Atlanta, Georgia, 10 days prior to the baseline
(TP1) PB and BM draws. The second timepoint (TP2) samples
were taken 20 days later, immediately prior to administration of
the anti-malarial drug pyrimethamine for the first time and 7 days
before sampling of the first post-Drug timepoint (TP3). After a
further 3 weeks, a second round of drug treatment immediately
followed the TP4 sampling. Consequently, TP1 and TP2 represent
pre-drug samples that nevertheless differ in their gene expression
and metabolic profiles, we suspect due to an acclimation period
of each animal in the new experimental environment. TP3, TP5,
and TP7 represent post-drug samples, and TP4 and TP6 repre-
sent inter-drug samples. Plasma metabolites were only profiled
following the drug administration period (TP3-TP7), but CBCs
were generated for all timepoints except TP4.
Our first objective was to define the variance components
of gene expression and metabolite abundance, namely the con-
tributions of among animal and among timepoint differences
to the overall variance. This was accomplished by generating
the PC that collectively account for 90% of the variance of
each omic data type and computing the weighted average of
the variance of each PC explained by animal or timepoint.
The variance explained by each PC is shown in Table 1 and
typically ranges from 25% for PC1 to less than 3% for PC5
(subsequent PC contribute too little to the overall variance to
significantly impact the evaluation of contributions of animal
and time). Figure 2A shows that for the BM and PB tran-
script data, as well as the CBC data, approximately 30% of
the variance is among animal and 10% among timepoints.
For the metabolomes by contrast, only 15% of the variance
is among animals with a slightly larger proportion due to
timepoint.
The unexplained residual variance could be due to undefined
biological sources, animal-by-timepoint interactions, random
sampling variance, or technical error. To control for contribu-
tions of the latter, we reduced the datasets by removing the
low-abundance features with the greatest coefficients of varia-
tion. Consistent with published findings (Rapaport et al., 2013),
both RNA-Seq and MS have a strong relationship between abun-
dance and variability, and based on the plots we adopted heuristic
cutoffs of 5 log2 units for the transcripts and 17 log2 units for
the metabolites. Figure 2B shows the variance components anal-
ysis based on the remaining features. In the PB, almost 70% of
the variance is among animals, and in the BM approximately
50%. The temporal contribution drops to less than 5% for the
PB, but increases to 20% for the BM. These results confirm that
measurement error is a major contributor to estimation for low
abundance transcripts with RNA-Seq. By contrast, the variance
components for both metabolite columns is relatively unaffected
by the data reduction, with both animal and time each contin-
uing to explain approximately 15% of the overall variance. This
Table 1 | Principle components of variation.
PC PVEa Animalb Timepointb Sig. drugc(effect)
BM1 14.5% 0.67 0.18 3 × 10−5(Pre high)
BM2 10.2% 0.92 0.02 0.09ns
BM3 7.1% 0.15 0.74 2 × 10−4(inter low)
BM4 6.8% 0.91 0.05 0.0052 (pre high)
BM5 5.8% 0.80 0.13 0.011 (post low)
PB1 12.0% 0.94 0.02 0.59ns
PB2 8.2% 0.97 0.01 0.48ns
PB3 7.4% 0.87 0.01 0.75ns
PB4 7.0% 0.97 0.01 0.98ns
PB5 5.5% 0.12 0.14 0.36ns
AE1 17.3% 0.23 0.41 0.35ns
AE2 8.9% 0.13 0.47 0.14ns
AE3 7.3% 0.23 0.47 0.58ns
AE4 6.2% 0.41 0.34 0.13ns
AE5 4.9% 0.22 0.37 0.07ns
C18_1 18.5% 0.28 0.23 0.17ns
C18_2 9.3% 0.20 0.59 0.11ns
C18_3 6.6% 0.40 0.17 0.15ns
C18_4 6.3% 0.28 0.31 0.49ns
C18_5 4.8% 0.22 0.38 0.38ns
aAmount of total variance explained by the PC.
bAmount of variance explained by Animal or Timepoint.
cSignificance of Drug effect (pre vs. post vs. inter for transcriptome; post vs.
inter for metabolome), also showing which effect was differentiated.
may reflect filtration of the metabolites with the highest technical
variance during peak calling.
HIERARCHICAL CLUSTERING OF THE OMIC DATA
The preceding analysis tells us that both animal and time influ-
ence gene expression, but not which animals or timepoints are
more similar. A quick means of visualizing these relationships is
by two-way hierarchical clustering (Figure 3; Eisen et al., 1998).
Applied to the raw data, in a joint analysis of the BM and PB,
the gene expression of the two tissue types is clearly distinct,
and the greater contribution of animal to the PB than the BM
is seen by the perfect clustering of each of the seven timepoints
within each animal grouping (Figure 3A). In the BM, there is
some mixing of samples across animals, but it is also striking
that TP4 is somewhat distinct since the data from four of the
five animals cluster together. After standardization to z-scores for
each gene, which removes the effect of overall abundance level for
each transcript on the hierarchical clustering, these relationships
are largely maintained (Figure 3B). The separation of TP4 in the
BM is enhanced, although the clustering within animals is dis-
rupted for a few PB samples. The situation for the metabolome is
very different (Figure 3C) as neither the animals nor timepoints
form discrete clusters. Both LC columns have almost identical
topologies (data not shown), and technical variability does not
explain these results since almost without exception all three tech-
nical replicates of each metabolite sample cluster adjacent to one
another.
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FIGURE 2 | Principal component variance component analyses. Bar
graphs show the weighted average contribution of among animal (red) and
among timepoint (blue) variance to gene expression, metabolite, and
complete blood counts. (A) Full data set. (B) Reduced dataset after removal
of low abundance transcripts or metabolites.
With respect to blood cell counts, the hierarchical cluster-
ing topology of monocytes, lymphocytes, granulocytes, RBC,
and platelets did not correspond to either the transcriptome
or metabolome topologies. The final two timepoints (TP6 and
TP7) cluster to the exclusion of the earlier timepoints with
a couple of exceptions, and within the two large clusters the
individual animals are adjacent. However, there is no strong
relationship between blood cell counts and overall gene expres-
sion (Figure 3D). Since each blood cell type has a characteristic
expression profile which allows each cell to perform its spec-
ified role(s), including the limited mRNA complement in a
nuclear RBC, we hypothesized that the macaques that clustered
together in the expression profile would also have similar lev-
els of the major cell types. However, we do not observe such a
trend: macaques RCs13 and RWr13 (relative to RTi13, RUn13, and
RZe13) form two sets of transcript profiles, whereas RTi13 and
RWr13 are most similar for CBC with RZe13 the most variable.
Therefore, we conclude that the CBC is capturing information
about the system that is non-redundant with the transcriptome.
This result is particularly striking when considering that both
the transcriptome datasets as well as the CBC datasets have the
variance component of animal explaining more than 30% of the
variance.
INTEGRATION OF THE TRANSCRIPTOME AND METABOLOME PROFILES
These analyses suggest that the transcriptomes and metabolome
are poorly correlated overall across all timepoints and animals,
but do not exclude the possibility that subsets of features in the
BM, the PB, or the plasma may be co-regulated. To test this using
our top-down strategy, we evaluated the covariance between the
major PC of each of the four omic datasets. Figure 4 shows the
pairwise regression coefficients for each of the first 10 PC, allow-
ing for the possibility that minor PC involving strong covariance
of a small number of transcripts or metabolites may contribute.
The pattern that emerges is informative in many ways. Firstly,
it shows that the two metabolomic datasets are highly corre-
lated. This is to be expected since metabolites are being measured
from the same plasma sample; the difference between the two
datasets is the use of different liquid chromatography columns
to optimize peak resolution across different classes of metabolites
(broadly, sugars and amino acids on the AE anion exchange col-
umn, and lipids on the C18 column). PC1 and PC2 scores for the
two columns are highly significantly correlated; many lower PC
scores are also correlated. Unlike the metabolomic datasets, the
two transcriptomic datasets, representing the BM and PB, do not
show as much correlation (Figure 4, top left quadrant). Statistical
analysis however does indicate that PC1, PC2, PC3, and PC4 in
the PB are significantly correlated with PC2, PC4, PC1, and PC5
from the BM, respectively (Bonferroni corrected p < 0.05). Such
a result is not unexpected considering that the two compartments
have different functions yet one (blood) is composed of cell pop-
ulations derived from the other (marrow). In some cases the sign
of the regression is negative, but this is simply a function of PCA
which commonly reverses signs and order of PC due to sampling
variance. One difference between the compartments is that the
marrow containsmany cell types that are rapidly dividing whereas
most of the cells in the blood are likely to be post-mitotic and
terminally differentiated.
Strikingly, there is no significant correlation between the tran-
scriptome PC scores and the metabolome PC scores across ani-
mals and timepoints. Figure 4 (top right box) seems to show
some relationships, but none of these are significant after mul-
tiple testing correction. We also explored 2-block partial least
square analysis (González et al., 2012) to identify minor vari-
ance components that may correlate in a joint analysis, but did
not observe any significant enrichment between the two data
types. This could be explained by the fact that the transcrip-
tome of these two immune compartments is contained within
the cell whereas the metabolome that we are interrogating is in
the plasma. Furthermore, the plasma is not only influenced by
metabolites from blood cells, but by metabolites secreted from all
tissues in the body and taken up from the environment.
The correlation of the major PC between the PB and the
BM datasets is dominated by among animal differences from the
variance component analysis, but also includes a temporal com-
ponent. The pre-drug samples in the BM are distinct from the
post- and inter-drug samples, but TP4 is the most differenti-
ated. In the PB, the baseline sample (TP1) is most differentiated,
but TP4, and, even more strongly, TP5 are also somewhat diver-
gent from the remaining samples. To assess the significance of
the overlap, we extracted the genes that were up-regulated in
the TP4 samples from the BM and performed a binomial sign-
test of whether the same genes were up-regulated at TP5 in the
PB. The result was highly significant (p < 3 × 10−16). A similar
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FIGURE 3 | Two-way hierarchical clustering. Each heat map shows the
abundance of each transcript or metabolite (rows) in each sample
(column) with red indicating high expression, blue low, gray
intermediate. (A) Transcriptome, based on absolute log-2 intensity
estimates, and (B) based on standardized log-2 intensities, in both
cases combining both BM and PB in the same clustering. (C) Plasma
metabolome, where each column is a technical replicate, showing
almost perfect alignment of each of the three replicates of each
sample. (D) Complete blood counts are clustered with the branches of
the dendrogram colored according to the identity of the animal, and
cell types ordered as Red Blood Cells, Lymphocytes, Monocytes,
Platelets, and Granulocytes (R, L, M, P, G respectively). Each macaque
is abbreviated as C, T, U, W, or Z for RCs13, RTi13, RUn113, RWr13,
or RZE13 respectively, and numbers refer to timepoints.
result was obtained for the down-regulated genes, but the control
comparison of TP6 and TP7 in the PB for the same up- and down-
regulated genes and did not result in any enrichment (p = 0.74).
These data show that differential gene expression in the BM is
reflected in the PB with a time lag (though contamination of
BM with PB cannot be excluded). Note as well that in both tis-
sues the TP4/5 differentially expressed genes are similar to the
TP1 genes, but with opposite sign of effect, implying that genes
up-regulated at baseline are down-regulated at TP4/5, and vice
versa.
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FIGURE 4 | Pairwise correlation of principal components. Heatmap shows
correlations of the first 10 principal components for each of the four omic
datasets ordered by peripheral blood, bone marrow, AE and C18 (blue
negative, red positive, stronger hues indicate stronger correlation). The
highlighted boxes in the top left and bottom right quadrants show the
correspondence between PC scores for the two transcriptomes and two
metabolome columns, respectively; stronger colors along the diagonal
indicate that those PC are capturing similar signals. Although there are
scattered stronger colors in the top right quadrant comparing transcriptome
and metabolome, the actual correlations are not significant.
IDENTIFICATION OF DRUG-RESPONSIVE GENES AND METABOLITES
The major temporal component of variation is not a cyclical
response to drug administration, which would have produced a
pattern where TP3, TP5, and TP7 were distinct from TP4 and
TP6 and again from TP1 and TP2. None of the first 10 PC in
PB showed a significant effect of drug administration on gene
expression by analysis of variance with pre, inter and post lev-
els of drug (Table 1). We nevertheless employed three strategies to
identify potential drug-responsive genes: axis of variance analysis,
pathway-oriented analysis, and gene set enrichment analysis.
The requirement that PCs are orthogonal to one another
introduces a statistical bias that is well-known to obscure under-
lying biology (Biswas et al., 2008). Consequently, we employed
an alternate partitioning of the transcriptional variance based
on conserved patterns of covariance of axes of gene expression
that are observed in all large human PB transcriptome datasets
(Preininger et al., 2013). Each of 9 axes is defined by 10 BITs that
are highly co-regulated, and the first PC of these BITs is used as
a measure of activity of genes in the axis. Each axis is thought to
represent an aspect of immune function, such as T- or B-cell sig-
naling (Axes 1 and 3), innate immune activation (Axis 5) or an
interferon-related axis (Axis 7). We confirmed that the BIT are
co-regulated in macaques, in both the PB and the BM, and asked
whether they vary by animal or timepoint. Figure 5 shows highly
significant among animal effects in the BM for Axes 3, 5, and 7.
Importantly these data also capture a drug response effect that
is not evident from the standard principal components, as Axes
7 and 9 are clearly differentially expressed at TP3, TP5, and TP7
in the BM, representing the post-drug samples. Axis 7 is also sig-
nificantly divergent in the PB, as is Axis 3, while Axis 9 shows a
non-significant trend (Table 2).
Analysis of variance at the level of individual genes was also
effective at recovering timepoint specific responses in the BM, but
not initially in the PB: Table 3 lists the number of features signif-
icant at a False Discovery Rate of 5% (Benjamini and Hochberg,
1995). Recognizing that animal effects may obscure the tempo-
ral differences, we also ran the model with “animal” included as
a random statistical effect, and recovered almost twice as many
timepoint-responsive transcripts in the BM, and 292 in the PB.
Similarly, ANOVA of the metabolome yielded many more signifi-
cant timepoint-responsive metabolites after inclusion of “animal”
as a random effect.
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FIGURE 5 | Axis of variance analysis. Each plot shows the indicated Axis score (PC1 of the 10 BIT for the Axis) in the five animals (A–C) or at the seven
timepoints (D–F). In bone marrow, Axes 7 and 9 are significantly differentiated at TP3, 5, and 7, the post-drug timepoints.
Table 2 | Axes of variance analysis.
Axis Bone marrow Peripheral blood
PVE by PC1a Sig Animalb Sig Drugc PVE by PC1a Sig Animalb Sig Drugc
1 45 0.0034 0.0006 43 ns ns
2 77 8 × 10−6 0.0061 68 0.0002 0.0025*
3 63 1 × 10−10 0.0169* 91 2 × 10−13 ns
4 25 ns ns 41 0.0005 ns
5 55 5 × 10−6 0.0022 73 0.0003 ns
6 35 0.0066 0.0005 29 0.0002 ns
7 54 3 × 10−6 0.0008* 76 3 × 10−5 0.0267*
8 45 ns 0.0183 58 2 × 10−5 ns
9 35 0.0002 1 × 10−6* 44 0.0234 ns
aThe percent of variation in the BIT explained by PC1 (>35% implies strong covariance).
bThe signficance of the among-animal effect.
cThe significance of the pre-/post-/inter-drug treatment after removing the animal effect.
*Implies the post-drug treatment effect was extreme relative to pre- and inter-drug.
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The most interesting timepoint effect with respect to drug
exposure is where each of the post-drug timepoints is greater (or
less) than the immediately preceding pre-drug timepoint, namely
TP3 > TP2, TP5 > TP4, and TP7 > TP6. Again, this situation
was only observed in the BM: 73 genes were consistently greater
post-drug, and 25 consistently less strongly expressed post-drug,
but no genes satisfied this criterion in PB (paired t-test, p < 0.05
at each of the three comparisons in 5 animals). A list is provided
in the Supplementary data, and is notable for multiple immune-
related genes, including TLR4, IL1RAP, IL1RAP, IL10RB, and
MAP2K1.
PATHWAY-ORIENTED ENRICHMENT ANALYSES
We next visualized the broad distribution of gene expression in
pathways across the time course of pyrimethamine treatment
Table 3 | Differential gene expression between timepoints.
Data type Tissue Without animal With animal
in model in model
RNA-Seq Bone marrow 3678 6483
RNA-Seq Whole blood 0 292
AE MS Plasma 651 927
C18 MS Plasma 1254 1992
CBC Whole blood 10 13
Table shows number of genes significant at 5% FDR rate for each data type,
contrasting seven timepoints for RNA-Seq, and 5 timepoints for metabolomics.
by performing hierarchical clustering of a summary measure of
each of 270 KEGG pathways. For each pathway with at least five
transcripts expressed in both BM and PB, we generated the first
principal component (PC1) of all of the transcripts annotated to
the pathway, measured in all five monkeys at seven timepoints.
These pathway PC1 values were averaged across the monkeys,
and clustered by Ward’s method in JMP. Figure 6 shows heat
maps of the average PC1 scores for BM (A) and PB (B) with red
corresponding to a high positive score, generally high transcript
abundance, and blue a negative score, generally lower abundance
on average.
In the BM, we observed seven clusters of pathway PC1 scores,
with the major division of timepoints grouping TP1, TP2, and
TP3 separately from TP4 through TP7. There was no clustering of
pathways at the three post-drug timepoints (TP3, TP5, and TP7).
In the PB, we observed just six clusters of pathway PC1 scores,
with the major division of timepoints separating TP1, TP4, and
TP6 from the remainder. Again, there was no evident clustering
of the post-drug timepoints. The grouping of TP4 and TP6 corre-
sponds to expected absence of drug, as does the baseline TP1, but
this does not seem to relate to drug exposure since TP2 sampled
immediately prior to the first drug administration, groups with
the post-drug samples.
Comparing both sample types, 10% of the cluster identities in
the PB are explained by the cluster identities in the BM (Pearson
Chi-square, p < 10−6). However, this also means that the major-
ity of the pathways change their average PC1 profile between the
BM and the PB. There are nevertheless some interesting clusters.
FIGURE 6 | Differential representation of pathways across timepoints.
The two-way hierarchical heat maps summarize co-expression of genes
within pathways in the bone marrow (A) and peripheral blood (B). Data
points are the mean PC1 score for each of 270 KEGG pathways. Rows
are timepoints, and the major clusters of PC1 scores are indicated.
Black tick marks below the heatmap in (A) indicate pathways that
are significantly different for the contrast of post- versus pre-drug
treatment.
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For example, the small green cluster 2 to the left in Figure 6A that
is high prior to drug administration and low at the final three
timepoints includes Ras and Rap 1 signaling, purine metabolism,
and infectious disease response. By contrast, the yellow cluster 7
that is more highly expressed uniformly after first drug adminis-
tration includes inflammatory autoimmune pathways, as well as
extracellular matrix and cell adhesion. Most of the DNA repair
and recombination pathways show the inverse pattern (clusters
4 and 5) implying down-regulation after persistent exposure to
pyrimethamine, as might be expected due to reduction of cell
division in response to folate inhibition. In the blood, the small
blue-green cluster 5 that is high at TP4, TP5, and TP6 involves
diverse pathways indicating perturbation of a variety of aspects of
cellular physiology during that interval of time.
These trends were not necessarily consistent across all five
monkeys. Similar hierarchical clustering of the 270 pathway PC1
scores of all 5 animals showed that two (RCs13 and RWr13) have
quite similar profiles, while another two (RUn13 and RZe13) are
only similar if TP4 is withdrawn from the analysis. Intriguingly,
these pairs of monkeys were each housed together in the same
cage, but there is no way of knowing whether that is coinci-
dence or reflects an effect of shared environment. The result
does however underline the conclusion that any effect of drug
administration is to a large extent animal-specific.
TARGETED AND GENE SET ENRICHMENT ANALYSIS
A disadvantage of the pathway-oriented approach is that it
assumes that the covariance of genes within pathways that is cap-
tured by PC1 represents the most relevant aspect of perturbed
gene expression. A more common approach is to identify differ-
entially expressed genes and then ask whether they are enriched
in particular pathways. We thus applied Gene Set Enrichment
Analysis (GSEA) to the dataset, focusing on genes that are glob-
ally altered at the 5% FDR level following drug treatment, namely
different between the two pre-drug samples and all five post- and
inter-drug samples. In the BM, analysis of 4178 genes revealed
13 pathways down-regulated following pyrimethamine exposure,
and 12 pathways up-regulated, at p < 0.001 and FDR q < 0.01;
these are listed in Table 4. The down-regulated pathways reflect
functions in the cell-cycle and metabolism including nucleotide
biosynthesis andDNA repair, as well as oxidative phosphorylation
(and glycolysis/gluconeogenesis trends in the same direction).
The up-regulated pathways are all involved in immune signal
transduction. Notably, in many cases the gene expression appears
to be intermediate at TP3, suggesting a gradual transition in
response to first drug administration that was reinforced with
subsequent administrations and lasted several months.
A good example of this is provided by focused analysis of
the one-carbon pool by folate pathway, which we expected to
be influenced by pyrimethamine, since the drug functions by
inhibiting the enzyme dihydrofolate reductase (DHFR). The
pathway was too small to include in the GSEA, but neverthe-
less 12 of 17 genes expressed in the macaque and annotated to
KEGG map00670 are positively co-regulated in both BM and
PB samples, with PC1 capturing 51% and 40% of the variance,
respectively (Figures 7A,B). The trajectory of this score trends
downward beginning at TP3 in the BM and over half the variance
Table 4 | Gene set enrichment analysis.
KEGG ID Pathway name Size p FDR p
DOWN REGULATED AFTER PYRIMETHAMINE
3030 DNA replication 26 <0.001 <0.001
4110 Cell cycle 57 <0.001 <0.001
3410 Base excision rep. 18 0.002 <0.001
3420 Nucleotide excis’n 22 0.004 0.006
0072 Ox phosphoryl’n 45 <0.001 <0.001
0010 Glycolysis 23 0.011 0.019
0480 Glutathione 24 <0.001 <0.001
0240 Pyrimidine 37 <0.001 <0.001
0230 Purine 60 0.003 0.006
3040 Spliceosome 46 <0.001 <0.001
5016 Huntington’s 56 <0.001 <0.001
5012 Parkinson’s 44 <0.001 <0.001
5010 Alzheimer’s 53 <0.001 <0.001
5322 SLE 34 0.005 0.008
UP REGULATED AFTER PYRIMETHAMINE
4660 TCR signaling 44 <0.001 <0.001
4650 NK-mediated cytotox 34 <0.001 <0.001
4630 JAK-STAT signaling 36 <0.001 0.001
4070 PI signaling 19 <0.001 0.001
4210 Apoptosis 23 <0.001 0.011
4662 B cell receptor signaling 21 <0.001 0.014
4370 VEGF signaling 19 0.002 0.013
4150 mTOR signaling 19 0.002 0.015
4310 WNT signaling 42 0.007 0.022
4722 Neurotrophin signaling 40 0.007 0.025
4012 ErbB signaling 24 0.007 0.028
4514 Cell adhesion 37 0.007 0.031
is among timepoints (ANOVA p < 0.0001), whereas in the PB
there is no differential expression (Figures 7C,D).
In the PB, purine (KEGG map00230) and pyrimidine (KEGG
map00240) metabolism pathways both show a very large coor-
dinated reduction in PC1 after TP1, namely before the first
drug administration, and remain low throughout the experiment.
Similarly, oxidative phosphorylation (KEGG map00190) is dom-
inated by a transition that precedes drug administration, as is
glycolysis (KEGG map00010), although it occurs in the opposite
direction (i.e., gene expression increases). These results suggest
that the animals experienced a shift in their major mode of energy
production in the circulating blood cells after introduction into
the experimental cages. Fatty acid biosynthesis also shows inter-
esting patterns that we do not have space to describe in detail. All
of these observations await confirmation at the metabolite level
once the annotation of the m/z features on the platform is more
advanced.
BAYESIAN NETWORK ANALYSIS OF THE TRANSCRIPTOME
Finally, we adopted an orthogonal exploratory approach to
describe networks of highly co-regulated genes. Each of the 1000
genesmost differentially expressed relative to drug administration
in the BM samples (that is, in the comparison of post- vs. inter-
drug timepoints) were carried forward to quality-thresholded
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FIGURE 7 | Targeted analysis of the folate pathway. (A,B) Loadings of
the first two PC for each of 17 genes in KEGG map00670 (One carbon
pool by folate) in BM and PB, also indicating the percent variation
explained by each PC. Note that MTHFR switches direction effect
between the cell sources. (C,D) Corresponding profiles across the
timecourse, showing decline in PC1 generally in BM following drug
exposure, but no significant differential expression in PB. Colors
correspond to the five monkeys as in Figure 5.
clustering (De Smet et al., 2002). We identified 26 clusters of 10 or
more transcripts, the first 4 of which have at least 50 transcripts
each (Figure 8A). Permutation of sample labels across timepoints
or the entire data set never identified this degree of covariance:
full permutation of sample labels for each gene independently
recovered zero clusters, while permutation of timepoints within
animals for each gene independently yielded just one cluster with
two genes, indicating that the clusters found were not artifacts
of the underlying data distributions while also increasing confi-
dence that the clusters are biologically motivated. Permutation of
animals within timepoints recovered a similar number and size of
clusters as the true data, indicating that animal effects had been
largely (but not completely) removed in generating the residuals.
Since Bayesian network inference is typically much more robust
and reliable with many more than the 35 samples available in
this study, we increased the effective number of observations per
variable by treating each gene (at each timepoint) as an obser-
vation of the behavior if its cluster. To do this, we concatenated
the top 10 genes most closely correlated with the cluster centroid,
yielding 350 observations for each of the 26 clusters. The most
robust and likely connections in the emergent networks were then
determined by subsampling and permutation as described in the
Methods.
An efficient and powerful method for Bayesian network struc-
ture learning, the Sparse Candidate Algorithm (Friedman et al.,
1999), was used to uncover the potential connections between
the clusters. Networks were inferred for 1000 randomly generated
subsamples of 90% of the data for each gene to ensure the robust-
ness of the learning results; all connections shown in Figure 8B
satisfy the criterion that each connection must exist in at least
50% of all of the resampling simulations for the original data, and
in each of the three permutations of that data; we found an aver-
age overlap of 66.7% of interactions conserved between the orig-
inal dataset and each of the three shuffles for the BM data, with
13 connections consistently detected in all datasets (see detailed
descriptions of robustness testing in the Methods). Core features
of this BM network were further investigated by inspection, and
validated by gene set enrichment analysis (Subramanian et al.,
2005). For instance, cluster 1 shows complimentary patterns to
clusters 8 and 22, while it is most similar to clusters 20 and 24. The
core genes in each of these clusters suggest functions in immune
T-cell responses. Clusters 1 and 3 are “hubs” with a relatively high
degree of connectivity in a graph that is otherwise quite sparse.
Although there was little evidence for significant differential
expression among the three drug response classes (pre-, post-, and
inter-) in the PB, we nevertheless assessed whether the BM cluster
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modularitymay be present in the PB. Projected onto the PB,many
of the BM clusters appeared to be co-regulated. To statistically
validate this inference, for each cluster we computed the correla-
tion of each gene with the centroid in the PB data, and compared
the observed distribution with that of 100 random samples of the
same size as that cluster, taken from the 660 transcripts contained
in all of the clusters. Figure 8C shows the proportion of permuta-
tions showing a significant deviation in the direction of stronger
FIGURE 8 | Bayesian Network analysis. (A) The results of quality-based
clustering on BM transcriptional data provide tight clusters of coregulated
genes used as input for Bayesian network inference. (B) The resulting robust
network, defined as those connections present in at least 50% of all
subsample analyses for each of four different permutations of the dataset.
The size of nodes indicates the size of the clusters (also included in A), and
the size of edges connecting nodes reflects the relative likelihood of a
connection based on its overall frequency of occurrence across subsample
replicates. (C) Statistical testing of the significance of correlations within
clusters of PB data derived from BM data clustering. For each cluster, 100
random samples of genes of the same size of the cluster were compared to
the PB data using the BM clustering of genes. The distributions of gene
profile correlations to the centroid of their cluster were compared using a
one-tailed Kolmogorov–Smirnov test. Histogram bars represent the number
of random samplings showing statistically significant increases in correlation
of the actual data compared to random data. (D) The PB network derived
using BM clusters; of note there is one conserved connection between this
and the BM network.
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concordance in the observed data, providing good evidence for
cluster conservation in the PB for 12 of the 13 largest clusters,
as well as several of the smaller ones. Furthermore, the Bayesian
network approach identified a number of robust connections in
the PB data, showing an average 37.5% overlap between the orig-
inal data and any of the permutations, and three connections
were observed in common across all permutations (Figure 8D).
One of those three connections was observed in both the PB and
the BM, implying robust dependence of cluster 13 on cluster 2
between the two compartments. Of note, the genes in both of
these clusters have been implicated in 6 and 24 h responses to
the anti-tumor aminopeptidase inhibitor Tosedostat (Krige et al.,
2008). The other two connections (cluster 3 to 2, and cluster 4 to
12) are found in PB but not in BM, suggesting that not only is
there conservation of modularity between the compartments, but
that new relationships using the modularity of one compartment
can be observed in the other.
Application of a similar pipeline to the metabolome data also
revealed novel structure to the data. Since there are fewer differ-
entially abundant m/z features in the plasma, this analysis was
performed on 500 features for each column with relatively high
false discovery rates on the post- vs. inter-drug samples, namely
28% for C18 (p < 0.01) and 36% for AE (p < 0.031). Quality-
thresholded clustering identified 11 and 10 clusters respectively
with more than 5m/z features, and 4 and 3 with more than
10m/z features. The profiles of the larger clusters in each of the
two columns are concordant (Figures 9A,B), and most were also
recovered in a joint analysis of both columns, with approximately
double the number of features. This suggests that the two columns
reproduce the same tight clusters of metabolites across animals
and times, although the actual m/z values do not match, suggest-
ing that different ionizations or adducts may have been included
in the selected features for each column. After Bayesian Network
analysis, three robust connections were observed between AE
clusters, but none with the C18 data (Figures 9C,D).
To investigate possible integration of the metabolic and tran-
scriptional data types, we first simply performed correlation
analysis between the centroids of all of the clusters. The strongest
interaction that was identified had a correlation coefficient
of −0.61. Using Bayesian network inference on all clusters of
size greater than 10 between BM transcriptional data and AE
column metabolomics data (using only timepoints 3–7 for all
based on availability of metabolomics data), we found little in the
way of robust connections between the two data types (data not
shown). There were no connections conserved across 50% of the
subsampling analyses in each of the original and four permuted
datasets; however, relaxing this criterion slightly to include any
connection present for 50% of all subsampling runs across all
four datasets (not 50% in each individual dataset) revealed one
potential connection between the two data types.
DISCUSSION
This study with naïve healthy rhesus macaques precedes others
that will involve specific infection and treatment regimens, and,
importantly, it has served to establish logistics and methodolo-
gies for systems biological approaches requiring the monitoring
FIGURE 9 | Quality-thresholded clustering of metabolomics data.
Each plot shows the standardized levels of the indicated number in
parentheses of m/z features in Qt-clusters that have at least 5
features. The order of samples along the x-axis is {RCs18, RTi18,
RUn18, RWr18, and RZe18} at TP3, 4, 5, 6, and 7, and the solid blue
line indicates the centroid of the cluster. (A) AE column. (B) C18
column. (C,D) Bayesian networks assembled on clusters with five
metabolites and seven levels of discretization, and 80% subsampling
threshold, similar to the analyses used to generate the transcriptomic
networks in Figure 8B.
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and evaluation of clinical data, collection of PB and BM samples,
and the integrative analysis of multiple omics and other datasets.
The biological objective of this study was to use the combined
power of transcriptomic and metabolomic profiling to investi-
gate the effects of an anti-malarial drug on the physiology of the
PB and BM. Five rhesus macaques were injected with a prepa-
ration of uninfected Anopheles dirus salivary glands, to mimic an
inoculation of Plasmodium sporozoites, and then followed for 100
days with intermittent administration of pyrimethamine, a drug
known to have an effect on the BM.
Ideally the unbiased top-down analytical approach that we
adopted would identify components of variation in both the
transcriptional and metabolomic domains that covary with drug
administration, and enrichment analysis of both would point
to a common aspect of metabolic regulation such as nucleotide
biosynthesis. To some extent we were thwarted in this objective
by three findings: (i) there is very low correspondence between
the transcriptome and metabolome and no major components of
variation correlate with repeated pyrimethamine administration;
(ii) among animal effects dominate the transcriptome raising
the possibility that pyrimethamine responses are variable among
individuals and obscure any common response; and (iii) although
the metabolomics platform reports thousands of features, anno-
tation is not yet robust enough to support global enrichment
analysis in this dataset (but see Li et al., 2013, for encouraging
developments).
Additionally, we must acknowledge that this is a relatively
small study, with just five monkeys and seven timepoints. The
failure to detect strong drug responses or covariance of the blood
and transcriptome may simply be a function of lack of statis-
tical power. For example, although we can attribute the largest
PC to specific sources of variance, those explaining much less
than 10% of the variance might be regarded as noise, and are
unlikely to replicate. That is one reason why we turned to the Axis
of Variation analysis, since the axes have a more biological basis
that is not as dependent on sample size. The pathway-oriented
analysis also highlights how interpretation of single gene effects
must be placed within the context of the major sources of vari-
ance, in this case animal effects and some temporal shifts that
may not relate to drug administration. It is likely that much
larger studies would be required to detect strong transcriptome-
metabolome covariance: for example, our analysis of 20 strains
of Drosophila profiled on four diets with considerable techni-
cal replication did suggest some specific examples of covariance
despite general absence of correspondence of the major PC axes,
and even in the presence of large genotype-by-diet interactions
(Reed et al., 2014). Studies with hundreds of NHPs are imprac-
tical, so we must make do with analytical methods such as
those reported here, but recognizing that there is low power
and the potential to over-interpret those associations that are
detected.
Nevertheless, several key findings contradict our expectations
and highlight aspects of the biology that emerge frommulti-omic
analyses. Most striking is the magnitude of the among-animal dif-
ferentiation of the transcriptome. This is even stronger in the PB
than the BM, with almost perfect clustering of all seven time-
point samples within animals. Each of the major PC and Axes of
variation are significantly different among animals. In the BM, an
unknown variable caused TP4 to generate a markedly different
profile common to all five macaques, yet the individual profiles
return to the animal-specific baseline within weeks. Persistent
among-individual differential expression in the PB has also been
reported in humans (Whitney et al., 2003; GG unpublished), but
here we demonstrate for the first time that the differential expres-
sion is initiated in the BM and the data suggests that it precedes
and is independent of individual-specific environmental influ-
ences faced in the PB. Persistent inter-individual variation is less
marked in themetabolome, but nevertheless present as previously
observed by Park et al. (2009) in a human dietary intervention
study.
The temporal component of transcriptional variance shows
some sign of cycling with drug administration, but it is domi-
nated by timepoints that are not primarily associated with recent
administration of the drug. In the PB, TP1 is most divergent,
possibly indicating incomplete acclimatization of the animals to
their new experimental housing and experimental procedures.
Indeed, one of the pathways elevated at TP1 denotes a general-
ized stress response, as we have previously observed in captive
relative to free range red wolves (Kennerly et al., 2008). This
effect is much less in the BM, and since TP1 and TP2 differ
from the remaining timepoints for 2 of the first 5 PC and 3
of 9 Axes (e.g., Figures 5D,F). Consistent with the observation
that pyrimethamine has an effect on the BM (Wickramasinghe
and Litwinczuk, 1981) our data indicates that in the BM there
is a global impact of pyrimethamine that persists throughout
the experiment following the first administration. Then at TP4
in the BM and TP4 and especially TP5 in the PB, there is fur-
ther differentiation of gene expression consistent with a height-
ened response to the drug. TP4 is an inter-treatment timepoint,
over 20 days after the previous administration at a time when
pyrimethamine should no longer be in circulation based on its
half-life of 140 h (Almond et al., 2000). Based on this figure there
should nevertheless be around one third of the administered dose
still available at the post-drug timepoints (TP3, 5, and 7), but we
do not know to what extent it would be directly available to cells
in the BM or circulating in the blood. Consequently, it is possible
that the relatively weak drug effects are because the animals are
no longer functionally exposed to pyrimethamine at the sampled
timepoints. We have been unable to correlate the change at TP4
with any variable such as a change in handler or cage conditions.
The null hypothesis of no differential expression across time is
rejected, but we do not have a clear alternate hypothesis for the
effect.
In the metabolome, there is very good correspondence
between the PC and the hierarchical cluster profiles of the two
columns, but the major variance components do not correlate
with either animal or drug response. Since retention times dif-
fer between the columns, and m/z peaks included in feature
selection may be from different adducts for several metabo-
lites, it is not straightforward to combine the analysis of both
columns. The major temporal effect is at TP7, which shows a
correlated response across all five animals. It is unclear whether
this represents a long-term effect of more than two months of
drug treatment, or some other unidentified stimulus, but it has
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no correlate in the transcriptome. Several hundred metabolite
features are globally different in the post-drug samples, even
though the major PC also differentiate the post- and inter-drug
timepoints.
The antimalarial drug pyrimethamine interferes with folate
by inhibiting the enzyme dihydrofolate reductase and disrupts
the parasite life cycle by interfering with nucleotide metabolism
and replication. It also affects host metabolism, and in fact
folate supplementation is often used to sustain healthy erythro-
poiesis in pregnant women and infants (Titaley et al., 2010).
Gene set enrichment analysis (Subramanian et al., 2005) of the
transcriptome provides some evidence for effects on metabolism
and cell division. Briefly, contrasting the pre- with the post-
and inter-drug timepoints, some common pathways between the
BM and PB, as well as BM-specific changes, are observed. The
former are of a metabolic nature, including oxidative phospho-
rylation, pentose phosphate, glyoxylate, butanoate, and linoleic
acid metabolism; the latter include multiple KEGG pathways
related to the cell cycle such as DNA replication, recombina-
tion, and repair. Our Bayesian network approach also focuses
attention on regulation of cell division since one of the key
enrichments in the BM is with targets of Tosedostat, an anti-
cancer drug that antagonizes aminopeptidase activity (DiNardo
and Cortes, 2014). Results such as this generate hypotheses that
can be tested by targeted metabolomics and manipulation of gene
expression, suggesting a new integrative genomics approach to
pharmacogenetics.
Our top down analyses also provide some important lessons
regarding the joint use of different data integration strategies
in MaHPIC (or similar) experiments where a relatively small
number of individuals will be followed longitudinally during
an intervention. While the principal components approach effi-
ciently defines the major sources of variation, it misses important
biological results and is not obviously the best strategy for integra-
tion of multiple omic and immunological measures. In particular,
the axis of variation analysis picks up effects of drug admin-
istration on broad aspects of immune function, most notably
interferon-related gene activity highlighted by Axis 7 in both PB
and BM samples. It is unlikely in this case that the elevation
of this axis is due to viral activity, but this result and weaker
evidence for dysregulation of Axes 2 and 9 in the week after
pyrimethamine administration show that the network of immune
interactions is perturbed and that drug activity is not narrowly
restricted to the immediate effects of folate. Finally, given the
small number of animals and timepoints in this experiment, sta-
tistical power is low for formal hypothesis testing, but we begin
to show how Bayesian Network analysis can tease out interaction
effects that are not evident in univariate analysis or in analyses
designed to capture the largest overall components of variance.
The two immune compartments share clusters of co-regulated
gene modules, but the connectivity of these differs between BM
and PB samples. Plasmodium infection will have a much larger
impact on the animals’ physiology than the mock-inoculations
described here, providing ample opportunity for exploring
network-based modeling of the host-parasite interactions that
underlie malaria infections, immunity, pathogenesis, and severe
disease.
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